Revolutionizing cancer treatment: Exploring novel immunotherapeutics, checkpoints, bispecifics, and vaccines in development DOI
Anas Islam, Vijay Singh,

Pooja S. Murkute

et al.

Advances in immunology, Journal Year: 2024, Volume and Issue: unknown

Published: Jan. 1, 2024

Language: Английский

Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion DOI Creative Commons

Xixi Liu,

Kenneth K.W. To,

Qinsong Zeng

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 3, 2025

The crosstalk between immunity and cancer in the regulation of tumor growth is considered a hallmark cancer. Antitumor refers to innate adaptive immune responses that regulate development proliferation. Tumor evasion represents major hindrance effective anticancer treatment. Extracellular vesicles (EVs) are nano-sized lipid-bilayer-enclosed particles secreted extracellular space by all cell types. They critically involved numerous biological functions including intercellular communication. Tumor-derived (TEVs) can transport variety cargo modulate cells microenvironment (TME). This review provides latest update about how evade surveillance exploiting TEVs. First, biogenesis EVs cargo-sorting machinery discussed. Second, differentiation, activation, function via TEVs illustrated. Last but not least, novel antitumor strategies reverse escape summarized.

Language: Английский

Citations

1
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4 DOI Creative Commons
J Zeng, Yuan Fang, Zixuan Zhang

et al.

Oncogene, Journal Year: 2024, Volume and Issue: 43(29), P. 2244 - 2252

Published: May 28, 2024

Abstract The combination of programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies has potential for enhancing clinical efficacy. We described the development antitumor activity Z15-0, a bispecific nanobody targeting both PD-1 CTLA-4 pathways simultaneously. designed optimized mRNA sequence encoding referred to as Z15-0-2 through series in vitro vivo experiments, we established that significantly increased expression nanobody. Administration tumor-bearing mice led greater inhibition tumor growth compared controls. In aggregate, introduced novel have re-engineered it boost mRNA, representing new drug paradigm.

Language: Английский

Citations

6
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies DOI Creative Commons
Monika Granica, Gustaw Laskowski, Paweł Link-Lenczowski

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189274 - 189274

Published: Jan. 1, 2025

Language: Английский

Citations

0
Naringenin: a potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma DOI Creative Commons

Wenmei Wu,

Xiangyu Qiu,

Xiaofan Ye

et al.

Journal of Pharmaceutical Analysis, Journal Year: 2025, Volume and Issue: unknown, P. 101254 - 101254

Published: March 1, 2025

Language: Английский

Citations

0
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer DOI
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao

et al.

BioDrugs, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Language: Английский

Citations

0
The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT DOI Creative Commons
João Martins Gama, Paulo Ricardo Teixeira, Rui Caetano Oliveira

et al.

Onco, Journal Year: 2024, Volume and Issue: 4(3), P. 116 - 130

Published: July 1, 2024

Immunotherapy has paved the way for development of solid tumor new treatments in last decade. The approval immune checkpoint inhibitors such as anti PD-1/PD-L1 provided a revolution with optimal results. However, considerable proportion patients experience adverse therapeutic effects, and up to 50% may develop secondary resistance first three five years. This prompted need identifying targets immunotherapy that have good tolerance biosafety and, course, tumoral response, either alone or combination. Two these are Lymphocyte-activation gene 3 (LAG-3) T cell immunoglobulin ITIM domain (TIGIT). They responsible several interactions system, prompting an immunosuppressive phenotype microenvironment. Both LAG-3 TIGIT can be druggable, combination anti-PD-1/PD-L1, rather safe profiles making them attractive. In this review, we highlight some mechanisms their detection by immunohistochemistry, providing insight into use clinical setting.

Language: Английский

Citations

1
Baicalin attenuates PD-1/PD-L1 axis-induced immunosuppression in piglets challenged with Glaesserella parasuis by inhibiting the PI3K/Akt/mTOR and RAS/MEK/ERK signalling pathways DOI Creative Commons

Shulin Fu,

Jingyang Li,

Jiarui You

et al.

Veterinary Research, Journal Year: 2024, Volume and Issue: 55(1)

Published: July 29, 2024

Abstract Infection of piglets with Glaesserella parasuis ( G. ) induces host immunosuppression. However, the mechanism underlying immunosuppression remains unclear. Activation PD-1/PD-L1 axis has been shown to trigger Baicalin possesses anti-inflammatory and immunomodulatory functions. whether baicalin inhibits activation thus alleviates not investigated. In this study, effect on attenuation piglet induced by was evaluated. Seventy were randomly divided into control group, infection levamisole BMS-1 25 mg/kg 50 group 100 group. Following pretreatment levamisole, or baicalin, challenged 1 × 10 8 CFU . Our results showed that modified routine blood indicators biochemical parameters; downregulated IL-1β, IL-10, IL-18, TNF-α IFN-γ mRNA expression; upregulated IL-2 IL-8 expression in blood. Baicalin, increased proportions CD3 + T cells, CD4 CD8 cells – CD21 B splenocyte population, blood, inhibited TIM-3 activation. reduced p-PI3K, p-Akt, p-mTOR expression, p-MEK1/2/MEK1/2 p-ERK1/2/ERK1/2 ratios RAS expression. provided substantial protection against challenge relieved tissue histopathological damage. findings might provide new strategies for controlling other immunosuppressive diseases.

Language: Английский

Citations

1
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors DOI Open Access
Jyoti Malhotra, Amy Huang, Arya Amini

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(21), P. 3603 - 3603

Published: Oct. 25, 2024

Immunotherapy with PD-1/PD-L1 inhibitors is the standard method of care for treatment newly diagnosed advanced or metastatic NSCLC, without chemotherapy. Many tumors, however, develop resistance to these immunotherapy agents. There a need more effective therapies patients NSCLC in second-line setting and beyond. In this review, we present an overview novel immunotherapies being investigated regarding patients. We summarize completed, as well ongoing, trials investigating monotherapy combination inhibitors. These include immune co-stimulatory antibodies, T-cell agonists, oncolytic viruses, vaccines, TIL therapies, CAR-T therapies.

Language: Английский

Citations

1
Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders DOI Open Access
Corneliu Toader,

Călin Petru Tătaru,

Octavian Munteanu

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(24), P. 13614 - 13614

Published: Dec. 19, 2024

Neuroimmunology is reshaping the understanding of central nervous system (CNS), revealing it as an active immune organ rather than isolated structure. This review delves into unprecedented discoveries transforming field, including emerging roles microglia, astrocytes, and blood–brain barrier (BBB) in orchestrating neuroimmune dynamics. Highlighting their dual both repair disease progression, we uncover how these elements contribute to intricate pathophysiology neurodegenerative diseases, cerebrovascular conditions, CNS tumors. Novel insights microglial priming, astrocytic cytokine networks, meningeal lymphatics challenge conventional paradigms privilege, offering fresh perspectives on mechanisms. work introduces groundbreaking therapeutic innovations, from precision immunotherapies controlled modulation BBB using nanotechnology focused ultrasound. Moreover, explore fusion with neuromodulatory technologies, underscoring new frontiers for personalized medicine previously intractable diseases. By synthesizing advancements, propose a transformative framework that integrates cutting-edge research clinical translation, charting bold path toward redefining management era neuroimmunology.

Language: Английский

Citations

1
Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2 DOI
Yuan Yao,

Yanan Ren,

Xingguo Hou

et al.

European Journal of Nuclear Medicine and Molecular Imaging, Journal Year: 2024, Volume and Issue: 52(1), P. 36 - 47

Published: Aug. 19, 2024

Language: Английский

Citations

0